ATXN3 and neoplasm: In fact, we show here that suboptimal treatment with a lower dose of anti–PD-1 completely inhibited LLC1 syngeneic tumor growth owing to further elevation of the antitumoral immune response, providing a rationale for ATXN3 targeting in sensitizing antitumor immune therapy.